Novartis announced that the European Commission (EC) has approved Cosentyx (secukinumab) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to glucocorticoids or… read more.
Enhertu (trastuzumab deruxtecan) has been approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic solid tumors with HER2 expression (immunohistochemistry [IHC]… read more.
UCB announced that the FDA has approved the first self-administered once-daily, autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine… read more.
Roche announced that the FDA has approved Enspryng (satralizumab) for the treatment of adults with thyroid eye disease (TED), providing patients with the first and only at-home subcutaneous… read more.
Roche announced that the FDA has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved catumaxomab (Korjuny) to treat malignant ascites in adults when standard treatment of their cancer is no longer feasible…. read more.
The European Medicines Agency (EMA) has recommended the approval of 12 new products at its September meeting. This brings the number of new medicines approved this year to… read more.
Novartis announced that the FDA approved Rhapsido (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled… read more.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued nineteen positive recommendations between 17 and 21 September 2026, spanning oncology, rheumatology, dermatology, neurology,… read more.
The National Institute for Health and Care Excellence (NICE) has issued four Technology Appraisal decisions in September 2026, comprising three positive first recommendations and one negative decision. Decisions… read more.
Mirum Pharmaceuticals, Inc. and Incyte announced that the FDA has approved Atebrioz (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric… read more.
Bristol Myers Squibb announced that the FDA approved CAMZYOS (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
